We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
14 watching
Current Price
$6.9
$0.15
(2.22%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
2,496.29M
52-Week High
28.35
52-Week Low
4
Average Volume
2.53M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,496.29M
52-Week High28.35
52-Week Low4
Average Volume2.53M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Bausch Health Companies Inc. (the “Company”), formerly known as Valeant Pharmaceuticals International, Inc., is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices) which are marketed directly or indirectly in over 90 countries.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Accesswire
22days ago
LAVAL, QC / ACCESSWIRE / November 4, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced one de novo abstract that is being presented at The Liver Meeting® 2022...
Accesswire
26days ago
New Educational Resource Designed to Help Support the Podiatry CommunityCompany Also Adds 300 Questions to Existing Dermatology Board Review ChallengeLAVAL, QC / ACCESSWIRE / October 31, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ('Bausch Health') and its dermatology...
PR Newswire
1month ago
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022 Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022 PR Newswire LAVAL, QC, Oct. 5, 2022 CMS...
CNW Group - News Releases
2 months ago
Bausch Health and Glenmark Announce the approval of RYALTRIS in Canada Bausch Health and Glenmark Announce the approval of RYALTRIS in Canada Canada NewsWire LAVAL, QC, and MUMBAI, India, Sept. 23, 2022 - RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$6.9
$0.15
(2.22%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00